Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.

Neoplasia (New York, N.Y.) - 1 Jun 2026

Paudel Rupesh, Goller Simon, Schwarz Stefanie, Meder Katharina, Goebeler Matthias, Schmidt Marc

Abstract excerpt

RAS/RAF/MEK/ERK1/2 mitogen-activated protein kinase (MAPK) pathway-based treatments, typically combination therapies with inhibitors for oncogenic BRAF V600 (BRAFi) and MEK1/2 (MEKi), are important treatment alternatives to immunotherapy in advanced BRAF-mutated melanoma. However, their benefit is limited by frequent therapy resistance, i.e. persistence and progression/metastasis of tumor cells under sustained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Melanoma
Share to Axl Receptor Tyrosine Kinase
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kruppel-Like Factor 4

Share to Kruppel-Like Transcription Factors

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 41916083
DOI: 10.1016/j.neo.2026.101301
PMCID: PMC13068529

Genes

KLF4
AXL
BRAF
NRAS
KLF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.PMID 41916083Read ↗

Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.Semantic proximity Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growthSemantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity Read ↗

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint InhibitorsSemantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.Semantic proximity Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant MelanomaSemantic proximity Read ↗

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.